GlassScriptPhysician profile
John J Vargo
NPI 1992756795
$34,359.77
in general payments reported to CMS, 2019-2025
27 companies · $3,569 in 2025
The $3,569 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,039 · 2020: $1,024 · 2021: $1,907 · 2022: $6,060 · 2023: $4,446 · 2024: $9,315 · 2025: $3,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $4,267 · Travel and Lodging: $1,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,750.00 |
| Food and Beverage | $4,266.77 |
| Travel and Lodging | $1,313.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $13,623.74 | 2019-2025 | General - Endochoice, Spyglass, Exalt Model D |
| US Endoscopy | $11,250.00 | 2023-2025 | |
| Olympus Corporation of The Americas | $3,690.00 | 2022 | |
| Medtronic, INC. | $1,358.84 | 2023-2025 | Nexpowder, Gi Genius, Signet |
| Olympus Corporation | $1,230.00 | 2021 | |
| Steris Corporation | $835.15 | 2021-2025 | |
| Abbvie INC. | $376.53 | 2021-2025 | Linzess, Viberzi, Creon |
| Pentax of America, INC. | $371.64 | 2023-2025 | Pentax Medical, C2 Cryoballoon, C2 Cryoballoon Focal Controller |
| Olympus America INC. | $243.79 | 2019-2020 | |
| Covidien LP | $233.93 | 2019 | |
| Aries Pharmaceuticals, INC. | $174.10 | 2019 | |
| Creo Medical INC. | $148.33 | 2023 | Speedboat |
| Braintree Laboratories, INC. | $143.95 | 2024 | Suflave, Sutab |
| Madrigal Pharmaceuticals | $124.93 | 2025 | Rezdiffra |
| Fujifilm Healthcare Americas Corporation | $121.25 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Erbe USA INC | $96.11 | 2023 | |
| Apollo Endosurgery US INC | $61.70 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.20 | 2019-2025 | Xifaxan, Plenvu |
| Ambu INC. | $53.20 | 2020 | |
| Pfizer INC. | $38.46 | 2023 | |
| Stryker Corporation | $24.73 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $23.89 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.92 | 2020 | |
| Lumendi LLC | $16.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.32 | 2020 | |
| Intercept Pharmaceuticals, INC. | $14.75 | 2021 | |
| Shionogi INC | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vargo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.